Neurolixis CEO, Adrian Newman-Tancredi, PhD, DSc, was interviewed for an online event supported by the FRAXA Research Foundation and sponsored by WuXi AppTec. Dr. Newman-Tancredi commented Neurolixis' development of a novel treatment for Fragile X syndrome (FSX), a debilitating genetic orphan disease. Neurolixis is characterizing NLX-101, a small molecule Novel Chemical Entity, as a potential treatment for FXS. Recent data presented at the Gordon conference (Tuscany, Italy) showed that NLX-101 strongly protected transgenic Fragile X mice from audiogenic-induced seizures and lethality. Taken together with previous data on NLX-101's influence in animal models of mood and cognition, the new results suggest that it could constitute a promising treatment for several autism spectrum disorders, including FXS and Rett syndrome (see previous news). 

NLX-101 is in early Phase 1 clinical characterization and Neurolixis is looking for collaborative partnerships to support its development. 

See a video highlight of Adrian's interview on YouTube, together with a series of other interviews on Fragile X syndrome.
For a full transcript of the interview, see here.


Neurolixis Inc. offers a warm welcome to Violettte Richin, MSc, as research associate. Ms Richin trained as a pharmacist at the University of Lyon, France, with a particular interest in neuroscience and brain imaging. She joins Neurolixis in the context of a collaboration with the Lyon Neuroscience Research center (CRNL) in the team led by Prof. Luc ZIMMER where she will develop new brain imaging tools to investigate the activity of Neurolixis drug candidates, notably novel antidepressant compounds such as NLX-204. Ms Richin is registered with the doctoral training school at the University of Lyon under a ‘CIFRE’ funding scheme and will be co-supervised by Dr. Wael Zeinyeh at CRNL and Adrian Newman-Tancredi at Neurolixis.

See more information concerning Neurolixis' team.

LinkedIn profile of Violette RICHIN.

Neurolixis CEO, Adrian Newman-Tancredi, PhD, DSc, was interviewed by the regional business accelerator of Castres-Mazamet, in southern France, which has been supporting the company since 2014. Adrian outlined his background in neuroscience research, starting with doctoral research in the UK, before moving to industrial pharmaceutical research at Servier, Pierre Fabre and now Neurolixis. A recent highlight is the launch of a clinical trial on NLX-112 for treatment of dyskinesia in Parkinson's disease, the fruit of a decade of work on movement disorders (see previous press release). 
See full interview (in French) here.